Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022

SELL
$17.44 - $23.16 $3,610 - $4,794
-207 Reduced 1.32%
15,462 $322,000
Q1 2022

Apr 28, 2022

BUY
$17.03 - $22.67 $266,843 - $355,216
15,669 New
15,669 $355,000
Q1 2021

Apr 28, 2021

SELL
$20.53 - $25.22 $252,724 - $310,458
-12,310 Closed
0 $0
Q4 2020

Feb 02, 2021

BUY
$18.39 - $24.8 $13,130 - $17,707
714 Added 6.16%
12,310 $247,000
Q3 2020

Oct 16, 2020

BUY
$20.67 - $26.94 $15,543 - $20,258
752 Added 6.93%
11,596 $284,000
Q2 2020

Jul 16, 2020

BUY
$16.46 - $27.42 $178,492 - $297,342
10,844 New
10,844 $257,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Spearhead Capital Advisors, LLC Portfolio

Follow Spearhead Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.